Evidence map›Paper›PMID 32825658›Full record

ArticlePharmaceutics2020

Protein Expression Knockdown in Cancer Cells Induced by a Gemini Cationic Lipid Nanovector with Histidine-Based Polar Heads.

Natalia Sánchez-Arribas, María Martínez-Negro, Eva M Villar, Lourdes Pérez, José Osío Barcina, Emilio Aicart, Pablo Taboada, Andrés Guerrero-Martínez, Elena Junquera

Abstract read
In one paragraph

Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Natalia Sánchez-ArribasDepartamento de Química Física, Facultad de Ciencias Químicas, Universidad Complutense de Madrid, 28040 Madrid, Spain.ORCID 0000-0003-4236-1894
María Martínez-NegroDepartamento de Química Física, Facultad de Ciencias Químicas, Universidad Complutense de Madrid, 28040 Madrid, Spain.ORCID 0000-0002-9358-4425
Eva M VillarDepartamento de Física de Partículas, Facultad de Físicas e Instituto de Investigaciones Sanitarias (IDIS), Universidad de Santiago de Compostela, Campus Vida, E-15782 Santiago de Compostela, Spain.ORCID 0000-0003-4023-1375
Lourdes PérezDepartamento de Tensioactivos y Nanobiotecnología, IQAC-CSIC, 08034 Barcelona, Spain.
José Osío BarcinaDepartamento de Química Orgánica, Facultad de Ciencias Químicas, Universidad Complutense de Madrid, 28040 Madrid, Spain.
Emilio AicartDepartamento de Química Física, Facultad de Ciencias Químicas, Universidad Complutense de Madrid, 28040 Madrid, Spain.
Pablo TaboadaDepartamento de Física de Partículas, Facultad de Físicas e Instituto de Investigaciones Sanitarias (IDIS), Universidad de Santiago de Compostela, Campus Vida, E-15782 Santiago de Compostela, Spain.ORCID 0000-0002-2903-7857
Andrés Guerrero-MartínezDepartamento de Química Física, Facultad de Ciencias Químicas, Universidad Complutense de Madrid, 28040 Madrid, Spain.ORCID 0000-0001-8576-2896
Elena JunqueraDepartamento de Química Física, Facultad de Ciencias Químicas, Universidad Complutense de Madrid, 28040 Madrid, Spain.ORCID 0000-0002-0655-5782

Funding

Agencia Estatal de Investigación MAT2016-80266-RAgrupación Estratégica en Materiales-AEMAT ED431E 2018/08Comunidad de Madrid P2018/NMT-4389ERDF PT17/0019Instituto de Salud Carlos III PT17/0019Ministerio de Ciencia, Innovación y Universidades CTQ2017-88948-PMinisterio de Ciencia, Innovación y Universidades RTI2018-095844-B-I00Universidad Complutense de Madrid UCMA05-33-010Xunta de Galicia ED431C 2018/26
6 · The paper itself

Abstract

A histidine-based gemini cationic lipid, which had already demonstrated its efficiency as a plasmid DNA (pDNA) nanocarrier, has been used in this work to transfect a small interfering RNA (siRNA) into cancer cells. In combination with the helper lipid monoolein glycerol (MOG), the cationic lipid was used as an antiGFP-siRNA nanovector in a multidisciplinary study. Initially, a biophysical characterization by zeta potential (ζ) and agarose gel electrophoresis experiments was performed to determine the lipid effective charge and confirm siRNA compaction. The lipoplexes formed were arranged in L

Indexed as

amino acid-based gemini cationic lipidsgene knockdown efficiencyNon-viral gene deliveryprotein coronaprotein expressionsmall interfering RNA

Identifiers

PMID32825658
PMCPMC7558209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.